Skip to content
Ultragenyx
-
Ultragenyx wins FDA approval for Fayuvi gene therapy for Sanfilippo syndrome
Patients have an average lifespan of about 15 years, while an estimated 3,000 to 5,000 people in commercially accessible markets live with the condition.